Company Overview
Snapshot
Founded in January 2024 by Maya Hanum and Yotam Harnik, Tracells operates with 1–10 employees. The company has raised $1 million across two funding rounds from one investor. In April 2024, Tracells secured a grant from the Israel Innovation Authority.
Business overview
Tracells is a Health Tech & Life Sciences company specializing in non-invasive diagnostic testing for inflammatory bowel diseases (IBD). The company utilizes advanced RNA transcriptomics and AI-driven classifiers to analyze RNA profiles from intestinal cells via stool tests. This technology enables accurate diagnosis of IBD, assessment of inflammation severity and location, and prediction of therapy response. Tracells aims to provide a convenient, home-based testing alternative to invasive procedures like endoscopies, serving the pharmaceutical and broader healthcare and life sciences markets with precise and cost-effective disease monitoring and management solutions.
Log in to access full profile ›Company Intelligence Q&A
- When was Tracells founded and by whom?
- Tracells was founded in January 2024 by Co-Founder & CEO Maya Hanum and Co-Founder & CTO Yotam Harnik.
- What is Tracells' core technology?
- Tracells uses advanced RNA transcriptomics and AI-driven classifiers to analyze RNA profiles from intestinal cells for non-invasive diagnostic testing of inflammatory bowel diseases (IBD).
- What is the primary application of Tracells' diagnostic tests?
- Tracells' diagnostic tests are primarily used for the accurate diagnosis of IBD, assessment of inflammation severity and location, and prediction of therapy response, aiming to replace invasive procedures.
- What is Tracells' current employee count?
- Tracells currently has 1–10 employees.